Active Ingredient History
Pirarubicin (INN) is an anthracycline drug. An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Administration, Intravesical (Phase 2)
Breast Neoplasms (Phase 4)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Transitional Cell (Phase 2)
Drug-Related Side Effects and Adverse Reactions (Phase 2/Phase 3)
Enteropathy-Associated T-Cell Lymphoma (Phase 4)
Lymphoma, B-Cell (Phase 4)
Lymphoma, Large-Cell, Anaplastic (Phase 4)
Lymphoma, T-Cell (Phase 4)
Medulloblastoma (Phase 4)
Multiple Myeloma (Phase 4)
Neoplasms, Germ Cell and Embryonal (Phase 4)
Nephroureterectomy (Phase 2)
Progression-Free Survival (Phase 2/Phase 3)
Sarcoma (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Diseases (Phase 2)
Wilms Tumor (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue